These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27525404)

  • 61. [Ocular toxocariasis--case report].
    Moraru A; Panfil M; Totolici G; Brănişteanu D; Costin D; Schmitzer S
    Oftalmologia; 2014; 58(4):30-5. PubMed ID: 26117928
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Frequency of the antibody anti-Toxocara canis in a community along the Uatumã river, State of Amazonas].
    Damian MM; Martins M; Sardinha JF; Souza LO; Chaves A; Tavares Ade M
    Rev Soc Bras Med Trop; 2007; 40(6):661-4. PubMed ID: 18200421
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lack of evidence for Toxocara infection in Italian myelitis patients.
    Nicoletti A; García HH; Cicero CE; Portaro G; Giuliano L; Patti F; Sofia V; Noh J; Handali S; Zappia M
    Neurol Sci; 2020 Jan; 41(1):239-241. PubMed ID: 31332580
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recombinant expression of the larval excretory-secretory antigen TES-120 of Toxocara canis in the methylotrophic yeast Pichia pastoris.
    Fong MY; Lau YL
    Parasitol Res; 2004 Jan; 92(2):173-6. PubMed ID: 14655048
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [A case of hepatic abscess caused by toxocara].
    Jung JK; Jung JT; Lee CH; Kim EY; Kwon JG; Kim BS
    Korean J Hepatol; 2007 Sep; 13(3):409-13. PubMed ID: 17898557
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fuchs heterochromic cyclitis and ocular toxocariasis.
    Teyssot N; Cassoux N; Lehoang P; Bodaghi B
    Am J Ophthalmol; 2005 May; 139(5):915-6. PubMed ID: 15860302
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Seroprevalence of Toxoplasma gondii and Toxocara canis in a human rural population of Southern Rio Grande do Sul.
    Araújo AC; Villela MM; Sena-Lopes Â; Farias NADR; Faria LMJ; Avila LFDC; Berne MEA; Borsuk S
    Rev Inst Med Trop Sao Paulo; 2018; 60():e28. PubMed ID: 29972461
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Longitudinal myelitis caused by visceral larva migrans associated with Toxocara cati infection: case report.
    Fukae J; Kawanabe T; Akao N; Kado M; Tokoro M; Yokoyama K; Hattori N
    Clin Neurol Neurosurg; 2012 Sep; 114(7):1091-4. PubMed ID: 22424728
    [No Abstract]   [Full Text] [Related]  

  • 69. Related factors to human toxocariasis in a rural community of Argentina.
    Chiodo P; Basualdo J; Ciarmela L; Pezzani B; Apezteguía M; Minvielle M
    Mem Inst Oswaldo Cruz; 2006 Jun; 101(4):397-400. PubMed ID: 16951810
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Seroprevalence of Toxocara infection in children from southern Brazil.
    Schoenardie ER; Scaini CJ; Brod CS; Pepe MS; Villela MM; McBride AJ; Borsuk S; Berne ME
    J Parasitol; 2013 Jun; 99(3):537-9. PubMed ID: 23738711
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of follow-up of therapy with fenbendazole incorporated into stabilized liposomes and immunomodulator glucan in mice infected with Toxocara canis larvae.
    Hrckova G; Velebný S; Obwaller A; Auer H; Kogan G
    Acta Trop; 2007; 104(2-3):122-32. PubMed ID: 17915186
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Humoral immune response of pigs infected with Toxocara cati.
    Sierra MF; Ricoy G; Sosa S; Colavecchia SB; Santillán G; López CM; Mundo SL; Sommerfelt IE
    Exp Parasitol; 2020 Nov; 218():107997. PubMed ID: 32946882
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Seroprevalence of toxocariasis in Lebanon: a pilot study.
    Kanafani ZA; Skoury A; Araj GF; El-Khoury M; Sawaya RA; Atweh SF; Kanj SS
    Parasitology; 2006 May; 132(Pt 5):635-9. PubMed ID: 16426480
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Influence of maternal infection on offspring immune response in murine larval toxocariasis.
    Reiterová K; Tomasovicová O; Dubinský P
    Parasite Immunol; 2003 Jul; 25(7):361-8. PubMed ID: 14521578
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment-resistant neuromyelitis optica spectrum disorders associated with Toxocara canis infection: A case report.
    Kambe D; Takeoka K; Ogawa K; Doi K; Maruyama H; Yoshida A; Suenaga T; Kageyama T
    Mult Scler Relat Disord; 2017 Apr; 13():116-118. PubMed ID: 28427692
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Toxocara canis meningoradiculitis].
    Robinson A; Tannier C; Magnaval JF
    Rev Neurol (Paris); 2002 Mar; 158(3):351-3. PubMed ID: 11976596
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diagnosis of parasitic zoonoses by immunoenzymatic assays--analysis of cross-reactivity among the excretory/secretory antigens of Fasciola hepatica, Toxocara canis, and Ascaris suum.
    Romasanta A; Romero JL; Arias M; Sánchez-Andrade R; López C; Suárez JL; Díaz P; Díez-Baños P; Morrondo P; Paz-Silva A
    Immunol Invest; 2003 Aug; 32(3):131-42. PubMed ID: 12916704
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Endocrine immune interactions during chronic Toxocariasis caused by Toxocara canis in a murine model: New insights into the pathophysiology of an old infection.
    Del Río-Araiza VH; Nava-Castro KE; Alba-Hurtado F; Quintanar-Stephano A; Muñoz-Guzmán MA; CUenca-Micò O; Morales-Montor J
    Vet Parasitol; 2018 Mar; 252():173-179. PubMed ID: 29559144
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Application of Toxocara canis excretory-secretory antigens and IgG subclass antibodies (IgG1-4) in serodiagnostic assays of human toxocariasis.
    Watthanakulpanich D; Smith HV; Hobbs G; Whalley AJ; Billington D
    Acta Trop; 2008 May; 106(2):90-5. PubMed ID: 18343348
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Use of specific immunoglobulin G antibody avidity in the differential diagnosis of active and chronic Toxocara canis infections].
    Rychlicki W
    Wiad Parazytol; 2004; 50(2):229-36. PubMed ID: 16859028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.